TAS 102 mechanism of action compared to 5-FU
Por um escritor misterioso
Last updated 13 outubro 2024
Frontiers A Comparison of Bevacizumab Plus TAS-102 and TAS-102
Issues and limitations of available biomarkers for
Mechanism of acquired 5FU resistance and strategy for overcoming
Redefining Later-Line Therapy in Metastatic Colorectal Cancer - EMJ
Trifluridine/tipiracil overcomes the resistance of human gastric 5
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a
Metastatic colorectal cancer: Advances in the folate
5-fluorouracil and other fluoropyrimidines in colorectal cancer
Comparison of Phase III trials evaluating TAS-102 and regorafenib
Inhibitory activity of FTD and 5-FU against cancer cells sensitive
Recomendado para você
você pode gostar